5-Fluorouracil-Ebeve, 50 mg/ml 20 ml

A labor-inhibiting agent, an oxytocin receptor blocker. Atosiban is a synthetic peptide which is a competitive antagonist of human oxytocin at the receptor level. Atosiban binds to oxytocin receptors, reducing the frequency of uterine contractions and myometrial tone, leading to suppression of uterine contractility. Atosiban also binds to vasopressin receptors, inhibiting the effect of vasopressin, but has no effect on the cardiovascular system.

In the case of preterm labor in a woman, atosiban inhibits uterine contractions at recommended doses and provides the uterus with functional rest. Uterine relaxation begins immediately after administering atosiban and myometrial contractile activity is significantly reduced within 10 minutes, maintaining stable functional peace of the uterus (≤4 contractions per hour) for 12 hours.

Pharmacokinetics

Indications

Active ingredient

Composition

How to take, the dosage

Injected by IV infusion immediately after diagnosis of preterm labor in three steps: 1) an initial dose of 6.75 mg is administered for 1 min first; 2) an infusion of 300 mcg/min (infusion rate 24 ml/h, atosiban dose 18 mg/h) is given immediately thereafter for 3 h; 3) an extended (up to 45 h) atosiban infusion of 100 mcg/min (infusion rate 8 ml/h, atosiban dose 6 mg/h) is followed.

The total duration of treatment should not exceed 48 h. The maximum dose of atosiban for the entire course is 330 mg.

If there is a need for repeated administration of atosiban, it should also be started with step 1, followed by infusion (steps 2 and 3). Re-application can be started at any time after the first use of the drug and can be repeated up to 3 cycles. If uterine contractility persists after 3 cycles of atosiban therapy, another drug should be considered.

Interaction

Special Instructions

If premature rupture of membranes is suspected, the benefit of using atosiban to prolong labor should be weighed against the potential risk of chorioamnionitis.

Atosiban should be used with caution in multiple pregnancies and at 24-27 weeks’ gestation (due to insufficient clinical experience).

In case of persistent uterine contractions during administration of atosiban, uterine contractions should be monitored and the fetal heart rate should be monitored. Other medications should also be considered.

There is no experience with atosiban in patients with impaired hepatic or renal function.

Atosiban is not used in cases of abnormal placental attachment.

In cases of intrauterine fetal retardation, the decision to continue or to reintroduce atosiban depends on the assessment of fetal maturity.

As an oxytocin antagonist, atosiban can theoretically promote uterine relaxation and induce postpartum uterine bleeding, so the degree of blood loss after delivery should be continually assessed.

Atosiban does not affect the ability to drive and operate machinery

Atosiban does not affect the ability to drive and operate machinery.

Contraindications

Side effects

Digestive system disorders: very often (>1/10) – nausea, rarely – vomiting.

Metabolic system disorders: often (>1/100, <1/100) – hyperglycemia.

Nervous system disorders: frequently (>1/100, <1/100) – headache, dizziness; rarely (>1/1000, <1/100) – insomnia.

Cardiovascular system: often (>1/100, <1/100) – tachycardia, arterial hypotension, hot flashes.

Skin side: rare (>1/1000, <1/100) – itching, skin rash.

Social system: very rare (>1/10,000, <1/1000) – uterine bleeding, uterine atony.

Other: very rare (>1/10,000, <1/1000) – allergic reactions.